The drug reslizumab (trade name EU: Cinqaero, U.S.: Cinqair) has been approved in Germany since August 2016 for the treatment of severe eosinophilic asthma in adults. Reslizumab is an additional treatment option if treatment with high-dose corticosteroids and other asthma medications is no longer enough to manage the symptoms.
Asthma is the result of an exaggerated immune response. When the mucous membranes lining the lungs (bronchi) come into contact with certain irritants, the muscles of the airways may contract. Typical symptoms include episodes or "attacks" of wheezing, coughing and shortness of breath. Eosinophilic granulocytes are cells of the body's immune system. In eosinophilic asthma, patients have an increased number of these cells in their blood and phlegm.
Reslizumab is given every four weeks in the form of an infusion (an IV drip), entering the bloodstream directly through a vein. The exact dose will depend on the patient's body weight.
In 2017, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to look into the advantages and disadvantages of reslizumab compared with the standard treatments for the above groups of patients.
But the manufacturer did not provide any suitable data with which to do the assessment.
This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of reslizumab (EU: Cinqaero, U.S.: Cinqair).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code Book V. Dossier assessment; commission A17-02. April 11, 2017. (IQWiG reports; volume 505).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.